United Pharmaceutical Korea (CEO Deok-young Kang) and UNS Bio (CEO Won-ho Kang) announced on the 25th that they have signed a memorandum of understanding with Y Bilogics for the development of Antibody Drug Conjugate (ADC) anticancer drug new.
(From left) Park Young-woo, CEO of Y Biologics, and Kang Won-ho, CEO of United Pharmaceutical Korea and UNS Bio, signed a memorandum of understanding for the development of new ADC anticancer drugs. (Photo courtesy of Korea United Pharmaceutical)
Through this agreement, the three companies intend to conduct joint research on the development of new ADC anticancer drugs and introduce a new collaboration model for the development of innovative new drugs by combining each company’s specialist expertise.
First, Korea United Pharmaceutical is responsible for developing non-toxic small molecule drugs optimized for ADC. Korea United Pharmaceutical, which specializes in developing improved new drugs and new formulations, intends to develop payloads and produce ADCs with optimal drug effects as it possesses various original technologies and patented formulation technologies.
UNS-Bio, a new anti-cancer drug research institute jointly established by Korea United Pharmaceutical and Seoul National University Technology Holdings, is responsible for the ADC development and approval process, and Y Biologics, a new antibody drug development platform company, responsible for developing antibodies. which target ADCs .
Through this, the three companies are expected to increase their research capabilities for new drug development and efficiently manage the time and cost of new drug development.
Present at the agreement ceremony on this day were Kang Won-ho, CEO of Korea United Pharmaceutical and UN S-Bio, and Park Young-woo and Jang Woo-ik, representatives of Y Biologics, respectively.
CEO Kang Won-ho said, “We are happy to collaborate with a company that has the best technology in the field of antibody drug research and development. By signing this MoU, we will accelerate the development of anti-cancer drugs new innovation by making the most of each company’s strengths.”
#United #PharmaceuticalY #Biologics #developing #ADC #anticancer #drug
